HRP20201194T2 - Laktami kondenzirani s arilom i heteroarilom - Google Patents
Laktami kondenzirani s arilom i heteroarilom Download PDFInfo
- Publication number
- HRP20201194T2 HRP20201194T2 HRP20201194TT HRP20201194T HRP20201194T2 HR P20201194 T2 HRP20201194 T2 HR P20201194T2 HR P20201194T T HRP20201194T T HR P20201194TT HR P20201194 T HRP20201194 T HR P20201194T HR P20201194 T2 HRP20201194 T2 HR P20201194T2
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- halogen
- group
- membered heteroaryl
- aryl
- Prior art date
Links
- 125000001072 heteroaryl group Chemical group 0.000 title claims 28
- 125000003118 aryl group Chemical group 0.000 title claims 2
- 150000003951 lactams Chemical class 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 27
- 229910052736 halogen Inorganic materials 0.000 claims 21
- 150000002367 halogens Chemical class 0.000 claims 21
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 20
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 16
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 9
- 229910003827 NRaRb Inorganic materials 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 125000005842 heteroatom Chemical group 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 4
- -1 -OH Chemical group 0.000 claims 4
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 4
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 4
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 230000002159 abnormal effect Effects 0.000 claims 2
- 230000010261 cell growth Effects 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (12)
1. Spoj formule (II-A):
[image]
,
ili njegova farmaceutski prihvatljiva sol,
naznačen time što:
R1 je C1-C8 alkil, C1-C8 alkoksi, halogen, -OH, -CN ili -NR7R8, gdje svaki navedeni C1-C8 alkil ili C1-C8 alkoksi može biti supstituiran s jednim ili više R21;
R2 je C1-C8 alkil, koji može biti supstituiran s 1 do 3 R22;
R3 je H, C1-C8 alkil, C1-C8 alkoksi, halogen, -OH, -CN ili -NR7R8, gdje svaki navedeni C1-C8 alkil ili C1-C8 alkoksi može biti supstituiran s jednim ili više R23;
R4 se bira iz skupine koju čine H, halogen, C1-C8 alkil, C3-C8 cikloalkil, 3-12-eročlani heterociklil, C6-C12 aril, 5-12-eročlani heteroaril, -(C1-C4 alkil)Rz, -ORx, -CN, -C(O)Rx, -CO2Rx, -C(O)NRxRy, -SRx, -SORx, -SO2Rx, -SO2NRxRy, -NO2, -NRxRy, -NRxC(O)Ry, -NRxC(O)NRxRy, -NRxC(O)ORy, -NRxSO2Ry, -NRxSO2NRxRy, -OC(O)Rx i -OC(O)NRxRy;
svakog Rx i Ry se neovisno bira iz skupine koju čine H, C1-C8 alkil, C3-C8 cikloalkil, 3-12-eročlani heterociklil, C6-C12 aril i 5-12-eročlani heteroaril; ili se Rx i Ry može uzeti zajedno s N atomom na kojeg su vezani kako bi tvorili 3-12-eročlani heterociklilni ili 5-12-eročlani heteroarilni prsten, od kojih svaki može sadržavati 1, 2 ili 3 dodatna heteroatoma, koje se bira između O, N i S;
svakog Rz se neovisno bira iz skupine koju čine C3-C8 cikloalkil, 3-12-eročlani heterociklil, C6-C12 aril i 5-12-eročlani heteroaril; i
gdje svaki navedeni C1-C8 alkil u R4, Rx ili Ry i svaki navedeni C1-C4 alkil u (C1-C4 alkil)Rz može biti supstituiran s jednim ili više R24, a svaki navedeni C3-C8 cikloalkil, 3-12-eročlani heterociklil, C6-C12 aril, ili 5-12-eročlani heteroaril u R4, Rx, Ry, Rz, ili Rx i Ry uzet zajedno može biti supstituiran s jednim ili više R34;
svakog R5 se neovisno bira iz skupine koju čine halogen, -OH, =O, C1-C4 alkil, C1-C4 alkoksi, -CN, -NR9R10 i -C(O)NR9R10, gdje svaki navedeni C1-C4 alkil ili C1-C4 alkoksi može biti supstituiran s 1 do 3 supstituenta, koje se neovisno bira iz skupine koju čine halogen, -OH, C1-C4 alkoksi, -CN, -NR9R10 i -C(O)NR9R10;
svakog R7 i R8 se neovisno bira iz skupine koju čine H, C1-C8 alkil, C3-C8 cikloalkil, 3-12-eročlani heterociklil, C6-C12 aril, te 5-12-eročlani heteroaril; ili
R7 i R8 se može uzeti zajedno s N atomom na kojeg su vezani kako bi tvorili 3-12-eročlani heterociklil ili 5-12-eročlani heteroaril, od kojih svaki može sadržavati 1, 2 ili 3 dodatna heteroatoma, koje se bira između O, N i S;
gdje svaki navedeni C1-C8 alkil u R7 ili R8 može biti supstituiran s jednim ili više R27, a svaki navedeni C3-C8 cikloalkil, 3-12-eročlani heterociklil, C6-C12 aril, ili 5-12-eročlani heteroaril u R7, R8, ili R7 i R8 uzet zajedno može biti supstituiran s jednim ili više R37;
svaki R9 i R10 je neovisno H ili C1-C4 alkil; ili
R9 i R10 se može uzeti zajedno s N atomom na kojeg su vezani kako bi tvorili 3-12-eročlani heterociklil ili 5-12-eročlani heteroaril, od kojih svaki može sadržavati 1, 2 ili 3 dodatna heteroatoma, koje se bira između O, N i S;
gdje svaki navedeni C1-C4 alkil u R9 ili R10, te svaki navedeni 3-12-eročlani heterociklil ili 5-12-eročlani heteroaril u R9 i R10 uzet zajedno može biti supstituiran s 1 do 3 supstituenta, koje se neovisno bira iz skupine koju čine halogen, -OH, =O, C1-C4 alkil, C1-C4 alkoksi, -CN, -NH2, -NH(C1-C4 alkil) i -N(C1-C4 alkil)2;
m je 0 do 4;
svakog R21, R22, R23 i R24 se neovisno bira iz skupine koju čine halogen, C1-C8 alkil, -CN, =O, -C(O)Re, -CO2Re, -C(O)NReRf, -ORe, -SRe, -SORe, -SO2Re, -SO2NReRf, -NO2, -NReRf, -NReC(O)Rf, -NReC(O)NReRf, -NReC(O)ORf -NReSO2Rf, -NReSO2NReRf, -OC(O)Re, -OC(O)NReRf, C3-C8 cikloalkil, 3-12-eročlani heterociklil, C6-C12 aril i 5-12-eročlani heteroaril;
svakog Re i Rf se neovisno bira iz skupine koju čine H, C1-C8 alkil, C3-C8 cikloalkil, 3-12-eročlani heterociklil, C6-C12 aril i 5-12-eročlani heteroaril; ili
Re i Rf se može uzeti zajedno s N atomom na kojeg su vezani kako bi tvorili 3-12-eročlani heterociklilni ili 5-12-eročlani heteroarilni prsten, od kojih svaki može sadržavati 1, 2 ili 3 dodatna heteroatoma, koje se bira između O, N i S;
gdje svaki navedeni C1-C8 alkil, C3-C8 cikloalkil, 3-12-eročlani heterociklil, C6-C12 aril ili 5-12-eročlani heteroaril u R24, Re, Rf, ili Re i Rf uzet zajedno može biti supstituiran s 1 do 3 supstituenta, koje se neovisno bira iz skupine koju čine halogen, -OH, = O, C1-C4 alkil, C1-C4 alkoksi, C1-C6 haloalkil, C1-C6 hidroksialkil, C1-C4 alkoksi-C1-C6 alkil, -CN, -NH2, -NH(C1-C4 alkil) i -N(C1-C4 alkil)2;
svakog R27 se neovisno bira iz skupine koju čine halogen, -OH, C1-C4 alkoksi, -CN, -NR9R10, C3-C8 cikloalkil, 3-12-eročlani heterociklil, C6-C12 aril i 5-12-eročlani heteroaril, gdje svaki navedeni C1-C4 alkoksi, C3-C8 cikloalkil, 3-12-eročlani heterociklil, C6-C12 aril ili 5-12-eročlani heteroaril može biti supstituiran s 1 do 3 supstituenta, koje se neovisno bira iz skupine koju čine halogen, -OH, =O, C1-C4 alkil, C1-C4 alkoksi, C1-C6 haloalkil, C1-C6 hidroksialkil, C1-C4 alkoksi-C1-Ca alkil, -CN, -NH2, -NH(C1-C4 alkil) i -N(C1-C4 alkil)2;
svakog R34 i R37 se neovisno bira iz skupine koju čine halogen, C1-C8 alkil, -CN, =O, -C(O)Rc, -CO2Rc, -C(O)NRcRd, -ORc, -SRc, -SORc, -SO2Rc, -SO2NRcRd, -NO2, -NRcRd, -NRcC(O)Rd, -NRcC(O)NRcRd, -NRcC(O)ORd, -NRcSO2Rd, -NRcSO2NRcRd, -OC(O)Rc, -OC(O)NRcRd, C3-C8 cikloalkil, 3-12-eročlani heterociklil, C6-C12 aril i 5-12-eročlani heteroaril;
svakog Rc i Rd se neovisno bira iz skupine koju čine H, C1-C6 alkil, C3-C8 cikloalkil, 3-12-eročlani heterociklil, C6-C12 aril i 5-12-eročlani heteroaril; ili
Rc i Rd se može uzeti zajedno s N atomom na kojeg su vezani kako bi tvorili 3-12-eročlani heterociklilni ili 5-12-eročlani heteroarilni prsten, od kojih svaki može sadržavati 1, 2 ili 3 dodatna heteroatoma, koje se bira između O, N i S;
gdje svaki navedeni C1-C8 alkil, C3-C8 cikloalkil, 3-12-eročlani heterociklil, C6-C12 aril ili 5-12-eročlani heteroaril u R34, R37, Rc, Rd, ili Rc i Rd uzet zajedno može biti supstituiran s 1 do 3 supstituenta, koje se neovisno bira iz skupine koju čine halogen, -OH, =O, C1-C4 alkil, C1-C4 alkoksi, C1-C6 haloalkil, C1-C6 hidroksialkil, C1-C4 alkoksi-C1-C6 alkil, -CN, -NH2, -NH(C1-C4 alkil) i -N(C1-C4 alkil)2;
X i Z se neovisno bira iz skupine koju čine H, C1-C8 alkil, C2-C8 alkenil, C2-C8 alkinil, C3-C8 cikloalkil, 3-12-eročlani heterociklil, C6-C12 aril, 5-12-eročlani heteroaril, halogen, CN, -C(O)Ra, -CO2Ra, -C(O)NRaRb, -SRa, -SORa, -SO2Ra, -SO2NRaRb, -NO2, -NRaRb, -NRaC(O)Rb, -NRaC(O)NRaRb, -NRaC(O)ORa, -NRaSO2Rb, -NRaSO2NRaRb, -ORa, -OC(O)Ra ili -OC(O)NRaRb;
gdje svaki navedeni C1-C8 alkil, C2-C8 alkenil, C2-C8 alkinil, C3-C8 cikloalkil, 3-12-eročlani heterociklil, C6-C12 aril, ili 5-12-eročlana heteroarilna skupina mogu biti supstituirani s jednim ili više supstituenta, koje se neovisno bira iz skupine koju čine halogen, -CN, -C(O)Ra, -CO2Ra, -C(O)NRaRb, -SRa, -SORa, -SO2Ra, -SO2NRaRb, -NO2, -NRaRb, -NRaC(O)Rb, -NRaC(O)NRaRb, -NRaC(O)ORa -NRaSO2Rb, -NRaSO2NRaRb, -ORa, -OC(O)Ra, -OC(O)NRaRb, C3-C8 cikloalkil, 3-12-eročlani heterociklil, C6-C12 aril, te 5-12-eročlani heteroaril;
svaki Ra i Rb je neovisno H, C1-C8 alkil, C2-C8 alkenil, C2-C8 alkinil, C3-C8 cikloalkil, 3-12-eročlani heterociklil, C6-C12 aril ili 5-12-eročlani heteroaril, gdje svaki navedeni C1-C8 alkil, C2-C8 alkenil, C2-C8 alkinil, C3-C8 cikloalkil, 3-12-eročlani heterociklil, C6-C12 aril i 5-12-eročlani heteroaril može biti supstituiran s jednim ili više supstituenta, koje se neovisno bira iz skupine koju čine halogen, C1-C4 alkil, -OR14, -NR142, -CO2R14, -C(O)NR142, -SO2R14 i -SO2NR142, gdje je svaki R14 neovisno H ili C1-C4 alkil; ili
Ra i Rb se može uzeti zajedno s N atomom na kojeg su vezani kako bi tvorili 3-12-eročlani heterociklil ili 5-12-eročlani heteroaril, od kojih svaki može sadržavati 1, 2 ili 3 dodatna heteroatoma, koje se bira između O, N i S, gdje navedeni heterociklil ili heteroaril mogu biti supstituirani s jednim ili više supstituenta, koje se neovisno bira iz skupine koju čine halogen, -OH, =O, C1-C4 alkil, C1-C4 alkoksi, C1-C6 haloalkil, C1-C6 hidroksialkil, C1-C4 alkoksi-C1-C6 alkil, -CN, -NH2, -NH(C1-C4 alkil) i -N(C1-C4 alkil)2; i
Y je H, halogen, -OH ili C1-C4 alkoksi.
2. Spoj ili sol u skladu s patentnim zahtjevom 1, naznačen time što je R1 C1-C6 alkil ili halogen.
3. Spoj ili sol u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je R2 C1-C4 alkil, koji može biti supstituiran s 1 do 3 R22.
4. Spoj ili sol u skladu s patentnim zahtjevom 3, naznačen time što se svakog R22 neovisno bira između halogena, -C(O)NReRf, -ORe, -NReRf, -NReC(O)Rf i -NReSO2Rf.
5. Spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što se R4 bira iz skupine koju čine H, halogen, -CN i C1-C8 alkil, gdje navedeni C1-C8 alkil može biti supstituiran s 1 do 3 R24.
6. Spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što je R3 H, a R4 je H ili halogen.
7. Spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što se X i Z neovisno bira iz skupine koju čine H, C1-C8 alkil i C3-C8 cikloalkil, a Y je H.
8. Spoj ili sol u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što je m 0.
9. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 8, ili njegovu farmaceutski prihvatljivu sol, kao i farmaceutski prihvatljivi nosač ili pomoćnu tvar.
10. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 8, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju abnormalnog staničnog rasta kod subjekta.
11. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 10, naznačen time što je abnormalan stanični rast rak.
12. Kombinacija, naznačena time što je kombinacija spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 8, ili njegove farmaceutski prihvatljive soli, sa sredstvom protiv raka.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261740596P | 2012-12-21 | 2012-12-21 | |
EP17206218.4A EP3339303B9 (en) | 2012-12-21 | 2013-12-05 | Aryl and heteroaryl fused lactams |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20201194T1 HRP20201194T1 (hr) | 2020-11-13 |
HRP20201194T2 true HRP20201194T2 (hr) | 2021-09-17 |
Family
ID=49917684
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20180060TT HRP20180060T1 (hr) | 2012-12-21 | 2018-01-15 | Kondenzirani arilni i heteroarilni laktami |
HRP20201194TT HRP20201194T2 (hr) | 2012-12-21 | 2020-07-30 | Laktami kondenzirani s arilom i heteroarilom |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20180060TT HRP20180060T1 (hr) | 2012-12-21 | 2018-01-15 | Kondenzirani arilni i heteroarilni laktami |
Country Status (47)
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2780013A4 (en) | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF |
CA2862289C (en) | 2012-02-10 | 2019-11-26 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
AR092742A1 (es) * | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
AU2013361200A1 (en) | 2012-12-21 | 2015-07-23 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
WO2014151142A1 (en) | 2013-03-15 | 2014-09-25 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
US9969716B2 (en) | 2013-08-15 | 2018-05-15 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
MD4820C1 (ro) | 2014-06-17 | 2023-03-31 | Pfizer Inc. | Compuşi dihidroizochinolinonici substituiţi |
WO2015193768A1 (en) * | 2014-06-17 | 2015-12-23 | Pfizer Inc. | Aryl fused lactams as ezh2 modulators |
CN107148419A (zh) * | 2014-10-28 | 2017-09-08 | 葛兰素史密斯克莱知识产权(第2 号)有限公司 | Zeste增强子同源物2抑制剂 |
TW201636344A (zh) | 2014-12-05 | 2016-10-16 | 美國禮來大藥廠 | Ezh2抑制劑 |
EP3236962A2 (en) | 2014-12-23 | 2017-11-01 | University of Copenhagen | Treatment of cancer by inhibiting ezh2 activity |
MX2017012195A (es) * | 2015-03-27 | 2018-01-09 | Syngenta Participations Ag | Derivados heterobiciclicos microbicidas. |
UY36758A (es) * | 2015-06-30 | 2016-12-30 | Glaxosmithkline Ip No 2 Ltd | Inhibidores del potenciador del homólogo zeste 2 |
TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ezh2抑制劑 |
WO2017040190A1 (en) | 2015-08-28 | 2017-03-09 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide |
KR20180081587A (ko) | 2015-11-19 | 2018-07-16 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 벤조푸란 유도체, 이의 제조 방법 및 의학에서의 이의 용도 |
PE20190106A1 (es) * | 2016-05-05 | 2019-01-15 | Glaxosmithkline Ip No 2 Ltd | Inhibidores del potenciador del homologo zeste 2 |
US10457640B2 (en) | 2016-10-19 | 2019-10-29 | Constellation Pharmaceuticals, Inc. | Synthesis of inhibitors of EZH2 |
CN108699002B (zh) * | 2016-11-11 | 2021-11-09 | 上海海雁医药科技有限公司 | 1,5,7-三取代的异喹啉衍生物、其制法与医药上的用途 |
US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
CN109937200B (zh) | 2017-05-18 | 2020-09-11 | 江苏恒瑞医药股份有限公司 | 一种苯并呋喃类衍生物游离碱的晶型及制备方法 |
EP3626239A4 (en) | 2017-05-18 | 2021-03-10 | Jiangsu Hengrui Medicine Co., Ltd. | USE OF AN EZH2 INHIBITOR COMBINED WITH A BTK INHIBITOR IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF TUMOR |
CN106977483A (zh) * | 2017-06-02 | 2017-07-25 | 遵义医学院 | 一种二氟烷基取代的黄酮醇、异黄酮醇和香豆素类化合物的合成方法 |
MX2020004731A (es) | 2017-11-14 | 2020-10-28 | Pfizer | Terapias de combinacion de inhibidor ezh2. |
ES2923290T3 (es) | 2018-01-31 | 2022-09-26 | Mirati Therapeutics Inc | Inhibidores de PRC2 |
JP2021531340A (ja) | 2018-07-09 | 2021-11-18 | フォンダシヨン、アジール、デ、アブグルスFondation Asile Des Aveugles | 眼障害を治療するためのprc2サブユニットの阻害 |
CN111320582A (zh) * | 2018-12-17 | 2020-06-23 | 江苏恩华药业股份有限公司 | 一种类酰胺类衍生物及其中间体的制备方法 |
KR20200101219A (ko) * | 2019-02-19 | 2020-08-27 | 한미약품 주식회사 | 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도 |
EP4196483A1 (en) * | 2020-08-13 | 2023-06-21 | Hanmi Pharmaceutical Co., Ltd. | Novel dioxoloisoquinolinone derivatives and use thereof |
KR102386403B1 (ko) * | 2020-08-13 | 2022-04-15 | 한미약품 주식회사 | 신규한 디옥솔로이소퀴놀린온 유도체 화합물 및 이의 용도 |
WO2022179584A1 (zh) * | 2021-02-26 | 2022-09-01 | 南京药石科技股份有限公司 | 新型ezh2抑制剂及其用途 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3846412A (en) | 1971-03-18 | 1974-11-05 | Lepetit Spa | Dihydro-2-amino-isoquinolines and their derivatives |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
FR2889526B1 (fr) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
US20070093515A1 (en) | 2005-08-16 | 2007-04-26 | Arrington Mark P | Phosphodiesterase 10 inhibitors |
US20100113415A1 (en) | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
WO2011103016A2 (en) | 2010-02-19 | 2011-08-25 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
PT2566327T (pt) | 2010-05-07 | 2017-05-26 | Glaxosmithkline Llc | Indoles |
ES2534804T3 (es) | 2010-05-07 | 2015-04-28 | Glaxosmithkline Llc | Indazoles |
ES2528269T3 (es) | 2010-05-07 | 2015-02-06 | Glaxosmithkline Llc | Azaindazoles |
PL2614369T3 (pl) | 2010-09-10 | 2016-08-31 | Epizyme Inc | Sposób określania przydatności inhibitorów ludzkiego ezh2 w leczeniu |
US8946260B2 (en) | 2010-09-16 | 2015-02-03 | Novartis Ag | 17α-hydroxylase/C17,20-lyase inhibitors |
US20130310379A1 (en) | 2010-11-19 | 2013-11-21 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
AU2012223448B2 (en) * | 2011-02-28 | 2017-03-16 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
TW201733984A (zh) * | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
US9730925B2 (en) | 2011-09-30 | 2017-08-15 | Glaxomithkline Llc | Methods of treating cancer |
US9562041B2 (en) | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
WO2014049488A1 (en) | 2012-09-28 | 2014-04-03 | Pfizer Inc. | Benzamide and heterobenzamide compounds |
AU2013361200A1 (en) | 2012-12-21 | 2015-07-23 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
JP6067878B2 (ja) | 2012-12-21 | 2017-01-25 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | オキシトシンアゴニストとしてのペプチド |
MD4736C1 (ro) | 2012-12-21 | 2021-07-31 | Gilead Sciences, Inc. | Compus policiclic de carbamoilpiridonă şi utilizarea farmaceutică a acestuia |
CN105308036B (zh) | 2012-12-21 | 2019-06-21 | 普莱希科公司 | 用于激酶调节的化合物和方法及其适应症 |
UA111305C2 (uk) * | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
MA38276B1 (fr) | 2012-12-21 | 2018-03-30 | Sanofi Sa | Dérivés de l'exendine 4 pour l’utilisation dans le traitement des troubles du syndrome metabolique, y compris le diabete et l'obesite, ainsi que la reduction de l'apport alimentaire excessif. |
FR3000059A1 (fr) | 2012-12-21 | 2014-06-27 | Saint Gobain Placo | Composition pour plaques de platre et produits obtenus |
PT2935222T (pt) | 2012-12-21 | 2018-12-10 | Epizyme Inc | Inibidores de prmt5 e seus usos |
FR3000065A1 (fr) | 2012-12-21 | 2014-06-27 | Univ Lille Ii Droit & Sante | Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes |
MD4820C1 (ro) | 2014-06-17 | 2023-03-31 | Pfizer Inc. | Compuşi dihidroizochinolinonici substituiţi |
-
2013
- 2013-05-12 UA UAA201505087A patent/UA111305C2/uk unknown
- 2013-12-05 DK DK17206218.4T patent/DK3339303T3/da active
- 2013-12-05 KR KR1020157019806A patent/KR101712441B1/ko active IP Right Grant
- 2013-12-05 HU HUE17206218A patent/HUE050009T2/hu unknown
- 2013-12-05 CR CR20200273A patent/CR20200273A/es unknown
- 2013-12-05 AU AU2013365908A patent/AU2013365908C1/en not_active Ceased
- 2013-12-05 ES ES17206218T patent/ES2808987T3/es active Active
- 2013-12-05 TR TR2018/02791T patent/TR201802791T4/tr unknown
- 2013-12-05 HU HUE13817739A patent/HUE038238T2/hu unknown
- 2013-12-05 ES ES13817739.9T patent/ES2658974T3/es active Active
- 2013-12-05 NZ NZ708801A patent/NZ708801A/en not_active IP Right Cessation
- 2013-12-05 EP EP17206218.4A patent/EP3339303B9/en active Active
- 2013-12-05 PT PT138177399T patent/PT2935238T/pt unknown
- 2013-12-05 PL PL17206218T patent/PL3339303T3/pl unknown
- 2013-12-05 MY MYPI2015701733A patent/MY176307A/en unknown
- 2013-12-05 JP JP2015548808A patent/JP5909308B2/ja active Active
- 2013-12-05 EA EA201590879A patent/EA028317B1/ru unknown
- 2013-12-05 GE GEAP201313863A patent/GEP201706718B/en unknown
- 2013-12-05 EP EP13817739.9A patent/EP2935238B1/en active Active
- 2013-12-05 ME MEP-2020-147A patent/ME03793B/me unknown
- 2013-12-05 SI SI201330958T patent/SI2935238T1/en unknown
- 2013-12-05 DK DK13817739.9T patent/DK2935238T3/en active
- 2013-12-05 PT PT172062184T patent/PT3339303T/pt unknown
- 2013-12-05 CA CA2893339A patent/CA2893339C/en active Active
- 2013-12-05 RS RS20200917A patent/RS60582B9/sr unknown
- 2013-12-05 RS RS20180103A patent/RS56815B1/sr unknown
- 2013-12-05 PL PL13817739T patent/PL2935238T3/pl unknown
- 2013-12-05 CU CU2015000062A patent/CU24414B1/es unknown
- 2013-12-05 LT LTEP17206218.4T patent/LT3339303T/lt unknown
- 2013-12-05 SG SG11201504076XA patent/SG11201504076XA/en unknown
- 2013-12-05 MA MA38175A patent/MA38175B1/fr unknown
- 2013-12-05 SI SI201331756T patent/SI3339303T1/sl unknown
- 2013-12-05 CN CN201380066782.2A patent/CN104870435B/zh not_active Expired - Fee Related
- 2013-12-05 AP AP2015008574A patent/AP2015008574A0/xx unknown
- 2013-12-05 MY MYPI2020003405A patent/MY192259A/en unknown
- 2013-12-05 BR BR112015014678-3A patent/BR112015014678B1/pt not_active IP Right Cessation
- 2013-12-05 MX MX2015008058A patent/MX2015008058A/es active IP Right Grant
- 2013-12-05 MD MDA20150052A patent/MD4664C9/ro not_active IP Right Cessation
- 2013-12-05 PE PE2015001044A patent/PE20151090A1/es active IP Right Grant
- 2013-12-05 LT LTEP13817739.9T patent/LT2935238T/lt unknown
- 2013-12-05 WO PCT/IB2013/060682 patent/WO2014097041A1/en active Application Filing
- 2013-12-18 US US14/132,567 patent/US9040515B2/en active Active
- 2013-12-18 TW TW102146910A patent/TWI546293B/zh not_active IP Right Cessation
- 2013-12-19 AR ARP130104902A patent/AR094174A1/es not_active Application Discontinuation
- 2013-12-20 UY UY0001038712A patent/UY38712A/es not_active Application Discontinuation
- 2013-12-20 UY UY0001035225A patent/UY35225A/es not_active Application Discontinuation
-
2014
- 2014-02-28 NO NO14709442A patent/NO2961649T3/no unknown
-
2015
- 2015-03-09 US US14/642,274 patent/US20150175572A1/en not_active Abandoned
- 2015-05-26 CR CR20150279A patent/CR20150279A/es unknown
- 2015-06-16 PH PH12015501367A patent/PH12015501367A1/en unknown
- 2015-06-18 IL IL239520A patent/IL239520B/en active IP Right Grant
- 2015-06-18 TN TNP2015000281A patent/TN2015000281A1/fr unknown
- 2015-06-18 CL CL2015001733A patent/CL2015001733A1/es unknown
- 2015-06-19 GT GT201500190A patent/GT201500190A/es unknown
- 2015-06-19 MX MX2020002924A patent/MX2020002924A/es unknown
- 2015-06-19 DO DO2015000157A patent/DOP2015000157A/es unknown
- 2015-06-19 ZA ZA2015/04437A patent/ZA201504437B/en unknown
- 2015-07-21 EC ECIEPI201531579A patent/ECSP15031579A/es unknown
- 2015-09-30 HK HK15109626.6A patent/HK1208866A1/xx not_active IP Right Cessation
-
2017
- 2017-05-03 US US15/585,880 patent/US10246433B2/en active Active
-
2018
- 2018-01-15 HR HRP20180060TT patent/HRP20180060T1/hr unknown
- 2018-02-05 CY CY20181100137T patent/CY1119883T1/el unknown
- 2018-09-05 ME MEP-2018-8A patent/ME02980B/me unknown
-
2020
- 2020-07-30 HR HRP20201194TT patent/HRP20201194T2/hr unknown
- 2020-08-11 CY CY20201100746T patent/CY1123237T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20201194T2 (hr) | Laktami kondenzirani s arilom i heteroarilom | |
CL2017003316A1 (es) | Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen. | |
DOP2018000088A (es) | Amidas heterocíclicas como inhibidores de cinasas | |
SV2017005587A (es) | Nuevos derivados hidroxiester, un proceso para su preparacion y composiciones farmaceutacas que los contienen | |
CR20170590A (es) | Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
CO7160029A2 (es) | Compuestos de heterociclilo como inhibidores de mek | |
UY36734A (es) | Nuevos derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
CO2018007443A2 (es) | Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
MX351581B (es) | Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen. | |
HRP20220628T1 (hr) | Postupci i međuprodukti za pripremu lijeka | |
DOP2014000156A (es) | Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
SV2014004771A (es) | Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
CL2015002520A1 (es) | Compuestos novedosos de pirimidina y piridina y su uso. | |
MY179290A (en) | Post nerve injury rehabilitation effect-enhancing agent comprising alkyl ether derivative or salt thereof | |
CR20160031A (es) | Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
CR20150268A (es) | Compuestos novedosos | |
ES2626801T3 (es) | Compuestos de triazolopiridina como inhibidores de pde10a | |
ECSP16074478A (es) | Compuestos novedosos | |
CR20150456A (es) | Sal abexinostate novedosos asociados en forma cristalina, procedimiento de preparación y composiciones farmacéuticas que los contienen | |
PE20150966A1 (es) | Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina | |
UY35182A (es) | ?COMPUESTOS DE HEXAHIDROPIRANO[ 3,4-d][1,3]TIAZIN-2-AMINA? . | |
MX2016005993A (es) | Anfifilos biscationicos y triscationicos como agentes antimicrobianos. | |
WO2012075242A3 (en) | Controlled chemical release of hydrogen sulfide | |
BR112012030534A2 (pt) | moduladores de receptores 5-ht e métodos de uso dos mesmos | |
CR20160030A (es) | Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparación y composiciones farmacéuticas que los contienen |